![](/wp-content/uploads/2017/04/default_blog_image.jpg)
27 Jun, 2023 Overview of ALN-KHK Preclinical Development Program Presented at American Diabetes Association 83rd Scientific Sessions
We presented an overview of the preclinical development program for ALN-KHK, an investigational RNAi therapeutic for type 2 diabetes mellitus, at the American Diabetes Association (ADA) 83rd Scientific Sessions.